It is our pleasure and honour to welcome Dr. Julia Levy, co-founder of QLT, to Qu’s Board of Directors, where she will be joining current the Chairman, Dr. Hal Gunn, and Directors, Dr. Simon Sutcliffe and Mr. Robert Freeman. Dr. Levy first became involved with Qu Biologics as a member of their Scientific Advisory Board in April 2011 and subsequently as an investor. As the company continues to grow, and to make the important transition to becoming a full-fledged clinical stage company, Dr. Levy’s in-depth experience and understanding of both the regulatory and business aspects of the biopharma industry are particularly valuable. Qu Biologics is in the final stages of preparing their first clinical trial application to Health Canada for the treatment of moderate to severe Crohn’s disease.
“The next 12 months are going to be decisive for Qu Biologics, as we run our first clinical trial in Crohn’s disease with our lead candidate drug product, QBECO,” announced Hal Gunn, CEO, “and plan subsequent trials with the second drug product in our pipeline, QBKPN. With her proven leadership capabilities and experience in bringing drugs successfully to market, Dr. Levy will be an invaluable asset on our Board of Directors as we prepare to take advantage of the many opportunities before us.”
Dr. Levy’s Biography:
As co-inventor of Visudyne and co-founder of QLT, Dr. Levy served in several key senior positions at the company including Chief Scientific Officer as well as President and CEO. Under Dr. Levy’s leadership, QLT recorded the strongest period of growth in the company’s history and earned a reputation for achieving milestones, including FDA approval for Visudyne to treat age-related macular degeneration, the commonest cause of severe vision loss in the elderly. Dr. Levy has earned numerous awards and honours including an appointment as an Officer of the Order of Canada, the Female Entrepreneur of the Year for International Business, Pacific Canada Entrepreneur of the Year and the Future of Vision Award from the Foundation Fighting Blindness. In 2002 she received, along with Dr. David Dolphin, the Friesen-Rygiel prize for medical research and the Prix Galien Canada research award. In her honour, the Julia G. Levy Professorship in Ophthalmology Chair was created at Johns Hopkins Hospital Wilmer Eye Institute in 2004, the same year she was awarded the Lifetime Achievement Award from the BC Biotechnology Association. In 2009, the province of British Columbia permanently endowed the Julia Levy B.C. Leadership Chair in Macular Research at the University of British Columbia (U.B.C.) in partnership with U.B.C. and QLT.
Welcome Julia! Thank you so much for joining our team of Directors.